Blood test may track heart disease treatment
NCT ID NCT07196839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 50 adults with a heart condition called ATTR-CM to see if medications like tafamidis or acoramidis lower harmful amyloid proteins in the blood over time. Researchers will take blood samples at several visits to measure these proteins. The goal is to find out if a simple blood test can help doctors monitor how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TTR stabilizing therapy (e.g., tafamidis or acoramidis)
- What this could lead to
- If successful, this could lead to a simple blood test to monitor treatment response in ATTR-CM patients.
- What could go wrong
- This is a small observational study (50 participants) measuring biomarkers, not clinical outcomes. It may not prove that the therapy directly improves health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75248, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.